As the world’s largest directory of preclinical cancer models, we are excited to announce that we are further expanding our global network of CRO partners with the addition of Syngene International Ltd., an integrated contract research, development and manufacturing organisation (CRO/CDMO) providing scientific services - from early discovery to commercial supply.
Syngene brings to the partnership more than 25 years of experience in disease modelling, enabling us to further grow our global reach to serve more biopharmaceutical companies in their quest for the right preclinical cancer models to accelerate oncology drug development programmes.
At present, the Repositive Cancer Models Platform displays curated and standardised metadata from over 8,000 preclinical cancer models. Biopharmaceutical researchers can browse the available models with the option of filtering content by primary site, model type and subtype, gene mutation, variant, treatment, and treatment response. In vivo oncology researchers and in-house bioinformatics teams can rely on the platform for automated processing, organisation and streamlining of cancer model inventories, while the system’s easy-to-access interface allows complex modelling queries to be effortlessly performed.
We also offers the Cancer Models Scout, a specialist and confidential concierge service, which provides tailored model recommendations to researchers based on a search across our extensive global network of more than 20,000 preclinical cancer models. This helps to accelerate the sourcing of models for preclinical oncology studies, with a proven track record of saving researchers months to years by connecting them to the right models in a much faster timeframe.
More information about the Repositive Cancer Models Platform is available here.
Syngene cancer specific capabilities
Syngene has a large PDX tumour repository for head and neck cancers specific to Indian ethnic populations, with all demographic and characterized genotypic details. In addition, they have a robust in vivo platform to screen immune checkpoint inhibitors (Anti-PD1, Anti-PDL1, Anti-CTLA4, Anti-LAG3) across a set of validated humanized mouse model(s). They also have a wide range of validated syngeneic tumour models (CT26, MC38, 4T1, LLC, B16F10, NBT-II) and IO profiling data with checkpoint inhibitors (Anti-PD1, Anti-CTLA4 etc.).
Syngene has a team of experienced scientists with the ability to set up diverse efficacy models, and a wide range of experience in screening new chemical entities (NCEs) and large molecules – single fusion, full length, bispecific antibodies and antibody drug conjugates (ADCs).
As well as having a wide array of established oncology animal models, Syngene also customizes programs as per client needs to design CDX (Human & syngeneic), PDX, humanized mouse platform, immuno-oncology models, orthotopic models, angiogenesis, metastasis, biomarkers and PK/PD correlation.
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
Syngene’s 4200 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation.
With a combination of dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife, as well as 1.9 Mn sq ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading edge science, as well as multinationals including GSK and Merck KGaA.
For more details, visit www.syngeneintl.com
Want to learn more about our vendors? Contact us today at firstname.lastname@example.org for more information!